Invention Grant
- Patent Title: Mithramycin derivatives having increased selectivity and anti-cancer activity
-
Application No.: US17278070Application Date: 2019-09-20
-
Publication No.: US11692003B2Publication Date: 2023-07-04
- Inventor: Jurgen Rohr , Oleg Tsodikov , Markos Leggas , Caixia Hou , Joseph Eckenrode , Prithiba Mitra , Abhisek Mandal
- Applicant: University of Kentucky Research Foundation
- Applicant Address: US KY Lexington
- Assignee: University of Kentucky Research Foundation
- Current Assignee: University of Kentucky Research Foundation
- Current Assignee Address: US KY Lexington
- Agency: Stites & Harbison PLLC
- Agent Mandy Wilson Decker
- International Application: PCT/US2019/052118 2019.09.20
- International Announcement: WO2020/106357A 2020.05.28
- Date entered country: 2021-03-19
- Main IPC: C07H15/24
- IPC: C07H15/24
Abstract:
Mithramycin (MTM) short side chain ketone (SK) derivatives and MTM short side chain diketone (SDK) derivatives are provided. The MTM SK and MTM SDK derivatives are useful for treatment of cancer or neuro-diseases associated with an aberrant erythroblast transformation-specific transcription factor. Unique MTM SK and MTM SDK derivatives have increased selectively toward ETS transcription factor.
Public/Granted literature
- US20220033429A1 MITHRAMYCIN DERIVATIVES HAVING INCREASED SELECTIVITY AND ANTI-CANCER ACTIVITY Public/Granted day:2022-02-03
Information query
